[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100463263":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":37,"centralContacts":42,"locations":47,"responsibleParty":66,"collaborators":30,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":30,"enrollmentInfo":79,"targetDuration":30,"studyType":82,"phases":83,"briefSummary":86,"conditions":87,"keywords":30,"overallStatus":49,"whyStopped":30,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Texas Tech University Health Sciences Center","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Placebo","PLACEBO_COMPARATOR","Placebo group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg olive oil) after dinner",[13],"Dietary Supplement: Placebo",{"label":15,"type":16,"description":17,"interventionNames":18},"Low GG","ACTIVE_COMPARATOR","LOW GG group: subject will take one pill (150 mg olive oil) after breakfast and another pill (150 mg GG) after dinner",[19],"Dietary Supplement: Low GG",{"label":21,"type":16,"description":22,"interventionNames":23},"High GG","HIGH GG group: subject will take one pill (150 mg GG) after breakfast and another pill (150 mg GG) after dinner",[24],"Dietary Supplement: High GG",[26,31,34],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":30},"DIETARY_SUPPLEMENT","300 mg olive oil",[9],null,{"type":27,"name":15,"description":32,"armGroupLabels":33,"otherNames":30},"150 mg GG",[15],{"type":27,"name":21,"description":35,"armGroupLabels":36,"otherNames":30},"300 mg GG",[21],[38],{"name":39,"affiliation":40,"role":41},"Chwan-Li (Leslie) Shen, PhD","Texas Tech Health Science Center","PRINCIPAL_INVESTIGATOR",[43],{"name":39,"role":44,"phone":45,"phoneExt":30,"email":46},"CONTACT","8067432815","leslie.shen@ttuhsc.edu",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Lubbock","Texas","79430","United States","US",{"type":56,"coordinates":57},"Point",[58,59],-101.85517,33.57786,{"lat":59,"lon":58},[62,65],{"name":39,"role":44,"phone":63,"phoneExt":30,"email":64},"806-743-2815","Leslie.Shen@ttuhsc.edu",{"name":39,"role":41,"phone":30,"phoneExt":30,"email":30},{"type":67,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100463263","phase-1-annatto-derived-gg-for-statin-associated-myopathy-100463263",false,"NCT05312424","Annatto-derived GG for Statin-associated Myopathy","Effect of Annatto-derived Geranylgeraniol (GG) on Statin-associated Myopathy","GG-statin","Inclusion Criteria:\n\n* Age ≥40 of either sex\n* Statin-treated patients with muscle pain alone or accompanied by other symptoms.\n* Patients currently receiving a statin who developed new-onset myalgias in within 90 day of initiation or a dosage increase\n\nExclusion Criteria:\n\n* Malignancy or significant neurological or psychiatric disturbances, including alcohol or drug abuse.\n* Woman who is pregnant, breastfeeding, or of childbearing potential and not taking adequate contraceptive precautions.\n* Had CoQ10 supplement one month before starting the study.\n* Genetic musculoskeletal and neurologic disorder known to affect skeletal muscle metabolism\n* Had steroid medication one month before starting the study.",true,"ALL","40 Years",{"count":80,"type":81},95,"ESTIMATED","INTERVENTIONAL",[84,85],"PHASE1","PHASE2","To evaluate the effects of 3-months annatto-derived geranylgeraniol (GG) supplementation on statin-associated skeletal muscle health.",[88],"Myopathy; Primary","2025-09-05",{"date":91,"type":92},"2025-09-12","ACTUAL",{"date":94,"type":92},"2022-07-15",{"date":96,"type":81},"2027-12-31",{"name":5,"class":6},1]